They bought CRMD and ZIOP.
http://whalewisdom.com/filer/raymond-james-financial-services-advisors-inc#/tabholdings_tab_link

Keep an eye on ARTH, ph 3 anyday.

CRMD.
http://scibilitymedia.com/can-solving-problem-transform-cormedix-inc-nysemktcrmd/

From PTX board.
stocktrademan Friday, 08/12/16 10:17:09 AM
Re: Boot Hill post# 3629
Post #
3653
of 3659 Go
$PTX bullish 0.71

Trading notes:

1) Stats on who downgraded PTX to hold, yet has a performance success rate of only 36% and an average return of nearly -9%...research sources of information to verify what is presented...

[Suppressed Image]

http://goo.gl/GKrsNk


2) Don't get wrapped up in series of intraday trader videos, that seem to always be appearing, when the daily price is outside the upper bollinger band with the rsi above 70 (overbought)...now that it is known what is going on then just wait until the conditions change and its gone on to something else...remember it is based on math not a person or brand...and frequent posts do not really affect the chart it is too much money for anyone to move on their own...

[Suppressed Image]


Chart indicates bullish MACD divergence
parabolic sar supporting price
macd crossing 0 upwards ("the moneymaker")
stock has made a long term base and is making the turn upwards

[Suppressed Image]

You can get it for .73 right now in AH trading.

CEO is not on the call had a family emergency.

Pernix Therapeutics Holdings, Inc. (PTX) After Hours Trading
$.81* 0.04996.56%

http://public.viavid.com/player/index.php?action=refresh&eid=120643&rid=395714

I am seeing that. It was up yesterday also. I am heavy in PTX right now. I will be listening to the conference call after the close.

Griffin-ZIOP - Going for Gold with Immunotherapies Ziopharm’s R&D programs are on track and should be generating plenty of news before year end. Reiterate BUY and $21 target
Sure Griffin has banking relationship with ZIOP but no analyst has more access to Cooper and Kirk and Crystyna B is working with Kirk almost full time and while she likely can't share much with Markey, Markey is thoughtful and has about the best handle on ZIOP on Wall Street. Do not dismiss his comments. His target was looking good all last yr and then the sector meltdown and the ridiculous shorting % has kept it down - but like CLDA where people made fun of his target until the deal, Markey will ultimately be proven right and that he had the best grasp on the company.



GRIFFIN SECURITIES

Keith A. Markey, Ph.D., M.B.A.

Stock Symbol NYSE: ZIOP
Current Price $5.00
12 mos. Target Price $21.00

August 11, 2016

Ziopharm BUY
Company Update : Biotechnology

Going for Gold with Immunotherapies Ziopharm’s R&D programs are on track and should be generating plenty of news before year end.

¦ AML will soon be the target of two clinical programs.
The Company is preparing to initiate studies in the next few
months with two immune-therapies. One is a CAR T cell
targeting the differentiation antigen CD33 that has the potential
to target cancer progenitor cells. The market will likely extend
well beyond acute myeloid leukemia to include most myeloid
malignancies. The other program will test off-the-shelf primary
natural killer (NK) cells. This therapy has the potential to extend
the lives of medically fragile patients for whom the CAR T cell
may not be appropriate. The Phase 1 studies, which will likely
enroll patients with recurrent/refractory disease, are scheduled
to commence before year end.

¦ Preparations are under way to advance IL-12 into a pivotal
clinical trial. The ongoing study evaluating the therapy has
shown that the lowest dose tested has a survival benefit (8
months and counting vs. 3 – 4 months expected) for patients
with recurrent glioblastoma. The third cohort of patients is
receiving an intermediate dose of activator ligand and so,
the study should conclude soon. The survival benefit and
adverse events associated with the three veledimex doses (20,
30, and 40 mg/m2) will help in designing next year’s pivotal
study. Meanwhile, Ziopharm is preparing to initiate a clinical
trial of IL-12 with a PD-1 antibody, as preclinical research
demonstrated an additive effect with the combination.

¦ Two ongoing clinical trials will report data soon. Results
from the breast cancer study of the IL-12 gene therapy will be
presented at an oncology meeting in early October. And the
trial of the second-generation CD19-CAR T cell therapy may
provide news in December.

The Company is designing new immunotherapies. A T cell that
expresses a chimeric antigen receptor under the control of the
RheoSwitch® is showing promise in preclinical tests. This design
may permit T cell activity to be titrated to avoid toxicities without
curtailing the therapy entirely. An iterative process of design, build,
and test has reduced the time to produce CAR T cells to 14 days
and further improvements are likely. Also, considerable work is
going into employing the Sleeping Beauty transposon system to
create patient-specific immunotherapies based on T cell receptor
technology.

We are maintaining our BUY recommendation and $21 price
target. News from the clinic and the start-up of more trials,
including a pivotal study of IL-12 for glioblastoma, should stimulate
interest in ZIOP shares.

INVESTOR CONSIDERATIONS
We believe Ziopharm will provide a plethora of clinical and preclinical data in the next four months that will demonstrate the breadth and depth of its technology. Specifically, there are three venues where new information will likely be presented:

IL-12 breast cancer trial: European Society for Medical Oncology, October 7 – 11.
IL-12 glioblastoma trial: Society for Neuro-Oncology, November 17 – 20.
Second-generation CD19-CAR T cell trial: American Society of Hematology, December 3 – 6.

And as illustrated in the Figure 1, the Company will have six clinical trials under way later this year and another four studies starting in 2017 that include a registrational trial of IL-12 for recurrent brain cancer (GBM).

Figure 1. An Impressive 2016 R&D Pipeline

The clinical trials are only part of the Ziopharm R&D program, as a variety of other advances that have been made
at a preclinical level:
(i) The Company has been able to reduce the time required to produce CAR T cells (e.g., CD19-targeting) to 14 days using the Sleeping Beauty gene insertion technology. This is an important step toward generating personalized immunotherapies “at the bedside.” Further research will be necessary to reach
the ultimate goal with this type of therapy.
(ii) Ziopharm has already succeeded in producing off-the-shelf, primary natural killer (NK) cells. A key technology is a method for expanding harvested NK cells ex vivo without reducing their potency. This achievement underpins the Phase 1 trial that is scheduled to commence this year in patients with acute myeloid leukemia (AML). The immunotherapy may prove especially relevant for medically frail individuals who cannot tolerate the chemotherapy conditioning that typically precedes T cell infusions.
(iii) A RheoSwitch-controlled CAR T cell has been created to provide an added measure of safety to this type of therapy. At this juncture, we consider the results to be a proof of concept in demonstrating that expression of the receptor in this cell population can be regulated. Further work will likely be conducted to optimize the control/response mechanism.

With sufficient funds to support its operations and clinical development programs through 2017, Ziopharm seems well prepared to make significant headway in the immunotherapy field. As a result, we are maintaining our BUY recommendation and price target of $21. Given the amount of data expected in the months ahead, investors may wish to take advantage of ZIOP’s current valuation.


FINANCIAL REVIEW & VALUATION ANALYSIS
We have updated our model for the June-quarter financial results and made modest changes to our 2017 estimates.
Note that we have treated a non-cash $119.1 million charge related to the issuance of preferred stock to Intrexon under their revised collaboration agreement (see our report dated July 1st) as a non-recurring event and have excluded it from our income statement presentation.
QUARTERLY INCOME STATEMENTS

(Fiscal years end December 31st.)
? Data are in thousands, except for per-share figures. Estimates are in italics.
Excluding the non-cash charge for the preferred stock issuance, Ziopharm’s financial performance was near our estimates for the June quarter. As a result, we have made only slight adjustments to our near-term estimates.
ANNUAL INCOME STATEMENTS

(Fiscal years end December 31st.)
? Data are in thousands, except for per-share figures. Estimates are in italics.
Our projections are unchanged since our July 1st report that discussed the change in the collaboration terms between Ziopharm and Intrexon. We will update our long-range projections as the Company advances the CD33-CAR T cells and NK cells into clinical development. Presently, our financial model is based on the IL-12 gene therapy for glioblastoma (46%) and the CAR T cells for myeloid malignancies (54%).
t
VALUATION ANALYSIS
We calculated our price target by employing a discounted future value model. Specifically, we multiplied the projected 2020 share earnings of $1.41 by a price-earnings multiple of 40 and discounted that future value back three years at an annual rate of 37%. That resulted in a $21.93-a-share valuation, which we rounded to $21 for our price target

PTX up 8.38%. Earnings after close. I'm long.

Q2 2016 Pernix Therapeutics Holdings Inc Earnings Conference Call

Thursday, August 11, 2016 4:30 p.m. ET
Webcast Presentation

Click here for webcast

PTX earnings at 4.30pm. Watch for AH trade. Expected-.08 and 40.33 million.
http://reviewfortune.com/2016/08/08/current-pernix-therapeutics-holdings-inc-nasdaqptx-pt-means-stock-is-worth-almost-9/

I am long.

JMP on ZIOP
report out this a.m. on XON
This is the ZIOP portion.

HEALTH SECTOR UPDATE
ZIOPHARM Oncology
We remind investors that Ziopharm announced amendments to the ECC with Intrexon in the areas of
oncology and GvHD, decreasing operating profit rates payable to Intrexon from 50% to 20% for
programs not partnered with a third party. Note that this alteration excludes the companies’ existing
collaboration with Merck Serono (biopharmaceutical division of Merck KGaA). In addition, economics
from future sublicensing arrangements with third parties will be split evenly. In exchange for this
reduction in operating profits received, Intrexon obtained $120MM from Ziopharm in preferred stock,
along with a monthly dividend of 1% payable in additional preferred shares.
Intrexon explained that a reason behind the change in the agreement is the need for Ziopharm to be
able to raise capital. With a 50/50% operating profit split, it was anticipated that it would be difficult for
Ziopharm to raise the capital needed in the future to continue later-stage clinical development of a
broad array of cancer immunotherapy candidates. In addition, for potential strategic acquirers, the
50/50% split was seemingly unattractive. Intrexon views this amendment favorably as it enables
Ziopharm to better continue to develop its products.
Ziopharm anticipates achieving several milestones in 2016. Regarding Ad-RTS-hIL-12, the company
expects to initiate a combination clinical study with anti-PD-1 antibodies. In addition, preclinical
pediatric data is expected to be presented in the fall for brain tumor. On the CAR-T program, it
anticipates continuing the second-generation CD19 CAR-T clinical study, to initiate a lentiviral-based
CD33 autologous CAR-T Phase 1 study in relapsed or refractory AML (w/very poor prognosis), and to
initiate preclinical CAR-T studies in other hematological and solid cancers. As for TCR T-cells,
Ziopharm anticipates initiating TCR-modified, T-cell preclinical studies. Regarding the NK cell program,
management expects to initiate a Phase 1 study of off-the-shelf NK cells for AML. As for GvHD
programs, preclinical studies will be initiated.
Developments in the quarter include: 1) in June, the amendment of the ECC with Intrexon to improve
alignment; 2) at ASCO, the company presented Ad-RTS-hIL-12 Phase 1 data in brain cancer, with
favorable interim survival data; 3) at ASGCT, XON highlighted preclinical studies combining Ad-RTS-IL-
12 with checkpoint inhibitors in brain cancer; 4) published the first-in-human study with the non-viral
Sleeping Beauty delivery system for CD19 CAR-T autologous and allogeneic therapy.

Kitov Announces Issuance of U.S. Patent Securing Long-Term Exclusivity for KIT-302 Ahead of New Drug Application to the FDA

8/9/16, 10:00 PM
TEL-AVIV, Israel, August 10, 2016 /PRNewswire/ --

Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced that the United States Patent and Trademark Office (USPTO) issued patent # 9,408,837 covering Kitov's lead drug candidate KIT-302 which the Company expects to submit for a New Drug Application to the U.S. Food and Drug Administration by the end of 2016.

The patent, entitled "Ameliorating Drug-Induced Elevations In Blood Pressure By Adjunctive Use Of Antihypertensive Drugs," was issued on August 9, 2016 and will have a term that can extend to May 22, 2029. Kitov Pharmaceuticals is pursuing additional claims to inventions described in the U.S. Patent #9,408,837.

KIT-302 simultaneously treats pain caused by osteoarthritis and treats hypertension, which is a common side effect of certain stand-alone drugs that treat osteoarthritis pain. KIT-302 is comprised of two U.S. FDA approved drugs, celecoxib (the active ingredient in Pfizer's Celebrex®), for the treatment of pain caused by osteoarthritis and amlodipine besylate, a drug designed to treat hypertension.

"We are pleased with this newly granted patent for claims in connection with our KIT-302, representing a significant achievement for Kitov's combination drug developments," said J. Paul Waymack, MD the Chairman of the Board of Directors and Chief Medical Officer of Kitov. "We are committed to further developing the patent holdings over our proprietary assets in order to maximize value to our shareholders."

ARTH chart, data any day.
http://investorshub.advfn.com/uimage/uploads/2016/8/9/jvbng1-ARTH-2month.jpg

Titan Management Team to Host Conference Call at 4:15 p.m. EDT/1:15 p.m. PDT

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/09/16 -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform, today reported financial results for the second quarter ended June 30, 2016.

Titan reported $15.0 million in revenue for the second quarter of 2016, compared with approximately $0.8 million for the comparable quarter in 2015. License revenue in the second quarter of 2016 reflects the one-time milestone payment that was earned from development and commercialization partner Braeburn Pharmaceuticals, Inc. (Braeburn) upon approval of Probuphine® by the U.S. Food and Drug Administration (FDA) in May 2016. Revenue in the second quarter of 2015 reflects the amortization of the upfront license fee received from Braeburn in December 2012.

Total operating expenses, consisting primarily of research and development (R&D) expenses and general and administrative (G&A) expenses, were approximately $3.0 million in the second quarter of 2016, compared with approximately $1.9 million in the second quarter of 2015.

R&D expenses for the quarter ended June 30, 2016 were approximately $1.7 million, compared with approximately $1.1 million for the same period in 2015, an increase of approximately $0.6 million. The increase in R&D costs was primarily a result of increases in external R&D expenses related to the support of ProNeura product development programs, and increases in employee-related expenses and other R&D expenses. During the three months ended June 30, 2016, external R&D expenses related to product development programs were $0.9 million, compared with $0.4 million in the same quarter in 2015.

G&A expenses for the second quarter 2016 were approximately $1.2 million, compared with approximately $0.8 million for the same quarter in 2015, an increase of approximately $0.4 million. The increased G&A expenses were primarily related to a contractual fee obligation of approximately $0.2 million in connection with the milestone payment received under the Probuphine license, increases in non-cash stock compensation and employee-related costs. Net other expenses for the second quarter of 2016 were approximately $0.1 million, compared with $1.2 million in the same quarter of 2015. Net other expenses consisted primarily of non-cash losses on changes in the fair value of warrants.

Net income for the quarter ended June 30, 2016 was approximately $11.9 million, or approximately $0.58 per share, compared with a net loss of approximately $2.3 million, or $0.11 per share for the comparable quarter in 2015.

At June 30, 2016 Titan had cash of approximately $19.3 million, which the company believes is sufficient to fund operations at least through the end of 2017.

Probuphine Launch Highlights

Following FDA approval on May 26, 2016, the Probuphine subdermal implant was commercially launched through a specialty distributor in the second half of June; first patients were treated shortly thereafter.
As of the beginning of August, Braeburn had trained and certified more than 2,300 health care providers from all 50 states and Puerto Rico to provide Probuphine to their patients, thus surpassing the halfway point of its goal to certify 4,000 health care providers by the end of 2016.

To date, Braeburn has conducted meetings with 40 regional insurance plans as well as Medicare, Medicaid and the Veterans Administration, and has received positive responses for third-party payor coverage from all.

"FDA approval of Probuphine marked several significant milestones for Titan in the second quarter, most noteworthy among them being the launch of the first product based on our proprietary ProNeura long-term, continuous drug delivery platform," said President and CEO Sunil Bhonsle. "Probuphine continues to generate strong interest among the medical community.

This is a testament to the need for new medication-assisted treatments for opioid addiction and to Probuphine's potential contribution to the treatment landscape as the only approved implant for the maintenance treatment of opioid dependence in patients stabilized on moderate to low doses of buprenorphine, and the only treatment to deliver medication for up to six months."

Business Highlights

In April, data from the last Phase 3 trial of Probuphine was presented at the 47th Annual American Society of Addiction Medicine (ASAM) Annual Conference. The data indicates that participants who were clinically stable on sublingual buprenorphine at a dose of 8 mg or less per day maintained stability when transferred to Probuphine, and that they were more likely to sustain abstinence from illicit opioids throughout the six months than participants who remained on sublingual buprenorphine.

In May, the FDA approved Probuphine, the first product for the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine. The product was available in the second half of June and the first patients were treated with the Probuphine subdermal implant shortly thereafter.

In June, Titan received a $15 million milestone payment from Braeburn Pharmaceuticals for the FDA approval of Probuphine. Under terms of the license agreement, Braeburn will pay Titan tiered royalties on net sales in the U.S. and Canada at rates ranging from the mid-teens to low-twenties. Additionally, Titan is eligible for up to $165 million in milestone payments based on achievement of certain annual sales targets, and up to $35 million based on regulatory milestones for additional indications.
In June, Titan's stock was added to the broad U.S. market Russell® 3000 Index and the small-cap Russell 2000® Index as part of Russell Investments' annual reconstitution of its stock indexes.

This can provide broader exposure and potential interest in the Company among new institutional investors.

In July, the Journal of the American Medical Association (JAMA) published an article titled "Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine," detailing results of the final Phase 3 trial of Probuphine, PRO 814, which demonstrated Probuphine's non-inferiority to sublingual buprenorphine among abstinent adults with opioid dependence.

"On the heels of Probuphine's launch, we are in a strong financial position to advance development plans for our other ProNeura-based programs, including our ropinirole implant for Parkinson's disease and our ProNeura T-3 implant to treat hypothyroidism," said Marc Rubin, M.D., executive chairman of Titan. "We expect to file an investigational new drug application (IND) for our ropinirole implant for Parkinson's disease in the fourth quarter, following completion of non-clinical studies, and to hold a pre-IND meeting with the FDA for our T-3 implant product candidate within that same timeframe."

Conference Call

Titan management will host a live conference call at 1:15 p.m. PT / 4:15 p.m. ET on Tuesday, Aug. 9, 2016 to discuss the company's financial results for the second quarter ended June 30, 2016 and to provide an update on the ongoing product development plans. The call will be hosted by Sunil Bhonsle, president and CEO; Kate Beebe, Ph.D., executive vice president and chief development officer; and Brian Crowley, vice president of finance.

The live webcast of the call may be accessed by visiting the Titan website at www.titanpharm.com. The call can also be accessed by dialing 888-684-1282, participant code 4286498, five minutes prior to the start time. A replay of the call will be available on the company website approximately two hours after completion of the call and will be archived for two weeks.

PTX.

$PTX Nice pop today, one to watch for continuation tomorrow pic.twitter.com/PqLBdMhgqI

— Scott Elliott (@Scelliott81) August 9, 2016

PTX chart.

$PTX pic.twitter.com/bibvk7vQku

— Phil Martin (@fm23) August 9, 2016

PTX starting to move up. Earnings tomorrow.

Good. Thanks

Upperward limit?

Is there a maximum cap on warrants? Do they buy and sell just like common shares? KTOVW.

Your not talking about Byner are you? I was a die hard Browns fan at the time. I remember jumping up and down with joy thinking Byner scored.Then reality sunk in. That still hurts. The Browns are dead to me now I could care less. Anyways go ARTH!

I am long. Price and volume picking up so the message board chatter will pick up soon

They will be back very soon.

At market.

8k out. Selling 40m Worth of shares.

Anyone know where to go to look for clinical trials for dogs?

Any Cybersecurity people on here? MGT.
HARRISON, N.Y., Aug. 4, 2016 /PRNewswire/ -- MGT Capital Investments, Inc. (NYSE MKT: MGT) today announced the development of Clear Skies, a revolutionary new platform designed to allow a company to implement a layer of security for data stored in the Cloud. This allows a company to ensure any lapses of security at the Cloud level do not subject the company's data to breaches, effectively providing the same level of security as an on premise database.
"Founded on the tenants of security, anonymity and privacy, Clear Skies is an enterprise-level application that gives businesses and customers full control of their data and provides de-facto end-to-end encryption. Clear Skies provides the same end-user convenience and benefits as the traditional Cloud, but without the risk and consequences of hosting data on somebody else's servers, only to be hacked when they fail to keep us safe," said Eijah. "Privacy must come first. To see the true beauty of the sky we must first get rid of the clouds."
Powered by the Demonsaw technology, Clear Skies allows businesses to collaborate in real-time, synchronize and share files, audio and video chat, configure on-the-fly anonymous traffic routing networks similar to TOR, and secure applications that were previously vulnerable to hackers, such as clear-text email and web browsing. Clear Skies enables businesses and individuals to break free from the cyber security limitations of Cloud data storage, empowering them to take back control of their future.
The solution to cyber security threats is not to relinquish more of our data, but to keep it close where it is safest. Clear Skies is just the beginning to the groundbreaking ways that we can integrate the Demonsaw technology to meet the emerging needs of the Business world," said Mr. McAfee. "Behind every Cloud is a silver lining. Change is coming. MGT would like to welcome you to Clear Skies."
Increasingly, businesses have discovered that data storage in the Cloud is not the paradise that was once promised. Companies and individuals trust their most precious and sensitive information, freely given, to these online entities every day. As history has shown, when the companies managing the Cloud get hacked, their accountability is rare and the companies or individuals that whose data was exposed are left holding the bag.
While the Cloud may promise convenience, it cannot guarantee security. Through Clear Skies, companies will be able to access the benefits of the Cloud without surrendering control of their data.
About MGT Capital Investments, Inc.
MGT Capital Investments, Inc. (NYSE MKT: MGT) is in the process of acquiring a diverse portfolio of cyber security technologies. With cyber security industry pioneer, John McAfee, at its helm, MGT Capital is positioned to address various cyber threats through advanced protection technologies for mobile and personal tech devices, including tablets and smart phones. The Company is currently in the process of acquiring D-Vasive, a provider of leading edge anti-spy software, and Demonsaw, a provider of a secure and anonymous file sharing software platform.
MGT Capital intends to change its corporate name to "John McAfee Global Technologies, Inc." upon closing of the D-Vasive transaction.
For more information on the Company, please visit http://ir.stockpr.com/mgtci.
MGT Capital Investments, Inc.

HAYWARD, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (ANTH) today announced that the last patient in the Phase 3 CHABLIS-SC1 clinical study, evaluating blisibimod for the treatment of systemic lupus erythematosus, received their final study dose on July 27th. As described in the protocol, patients are followed for eight weeks after their last dose at which time the final safety data is collected. Due to timing of this final visit, the company expects topline efficacy and safety data will be available prior to the annual American College of Rheumatology Annual Meeting in November.

“We are very pleased that we have had our last patient dosed in this 52-week active dosing study,” said James Pennington, MD, Anthera's Interim Chief Medical Officer. “We continue to aggressively collect, analyze and finalize the CHABLIS-SC1 database as the final patients suffering from lupus complete the study. To date, the mean baseline SELENA-SLEDAI score, a measure of lupus disease activity, is 13.6 and in-line with our hypothesis of studying people with more severe disease.”

Topline data from the CHABLIS-SC1 will include the primary endpoint evaluation, a six-point reduction in the Systemic Lupus Erythematosus Responder Index (SRI-6) as well as safety and tolerability data from the study.

About CHABLIS-SC1

CHABLIS-SC1 is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, tolerability and immunogenicity of blisibimod in patients with seropositive, clinically-active lupus (SELENA-SLEDAI ≥ 10) who require corticosteroid therapy in addition to standard-of-care for treatment of their disease. The study enrolled 442 patients in 12 countries across Asia, Eastern Europe and Latin America. Patients received either 200mg of blisibimod or placebo in addition to their standard-of-care medication for 52 weeks. The primary endpoint of the CHABLIS-SC1 study will be clinical improvement in the SRI-6 response at 52 weeks. With 442 evaluable patients, the study is powered at 89% to detect a 14% treatment difference assuming a 25% placebo response rate. Key secondary outcomes from the study, including SRI-8, reduction in the number of lupus flares and steroid use, are intended to further differentiate blisibimod from currently available therapies. For more information on the CHABLIS-SC1 study, please visit http://www.anthera.com/clinical-studies/chablis_sc/.

About Blisibimod

Blisibimod is a selective peptibody antagonist of the B-cell activating factor (BAFF) cytokine that is initially being developed as a treatment for lupus. BAFF is a tumor necrosis family member and is critical to the development, maintenance and survival of B-cells. It is primarily expressed by macrophages, monocytes and dendritic cells and interacts with three different receptors on B-cells including BAFF receptor, or BAFF-R, B-cell maturation, or BCMA, and transmembrane activator and cyclophilin ligand interactor, or TACI. The BAFF-R receptor is expressed primarily on peripheral B-cells. Blisibimod consists of a novel BAFF binding domain fused to the N-terminus of the Fc region of human antibody. Blisibimod binds to BAFF and inhibits the interaction of BAFF with its receptors. The role of BAFF in lupus has recently been clinically validated in multiple late-stage clinical studies with an anti-BAFF antibody. We intend to advance the development of our BAFF antagonist, blisibimod, to exploit its broad potential clinical utility in autoimmune diseases, with initial focus on lupus. Blisibimod demonstrates anti-BAFF activity and has been shown to be safe and effective in selectively modulating and reducing B-cells in two Phase 1 clinical studies in lupus patients.

Looks like the MM’S just took out stops on MGT.

PTX trying to break a dollar. Another high volume day.

Anyone know anything about MRTX, it's moving up.

Old but 8 informative article on ARTH.
http://www.rdmag.com/article/2014/08/potential-new-route-stopping-surgical-bleeding

Old but 8 informative article on ARTH.
http://www.rdmag.com/article/2014/08/potential-new-route-stopping-surgical-bleeding

PTX and MGT.
0.870.19 (28.78%)
After hours: 0.870.01 (0.61%) as of 5:04 PM EDT
Prev Close 0.67
Open 0.70
Bid 0.875 x 1100
Ask 0.8799 x 4100
52wk Range 0.39 - 5.60
Day's Range 0.69 - 0.90
Volume 16,202,572 HUGH VOL AT THE CLOSE
Avg Vol (3m) 6,543,222
As of 4:00 PM EDT. Market closed.

MGT up 7.32%

ARTH DD.
http://archtherapeutics.blogspot.com/2015/06/arch-therapeutics-symbolarth-operated.html?m=1

http://ih.advfn.com/p.php?pid=nmona&article=72117381&symbol=MGT

FWIW MGT chart.

$MGT Charts from 8/1 – breaking the 50 DMA & EMA 13 today – a close above both levels would https://t.co/6SHjUgPqbS pic.twitter.com/fjZXAh7wMr

— Ospreyeye (@MyChartCoachcom) August 2, 2016